Drug maker GSK invests in gene profiling services

LONDON — Drug maker GlaxoSmithKline says second-quarter revenue was 7.3 billion pounds ($9.6 billion), up 4 percent when discounting currency shifts, amid a promising performance of a new shingles treatment.

Sales of the shingles treatment Shingrix made 167 million pounds, and the company increased its forecast for 2018 sales of the drug to as much as 650 million pounds. GlaxoSmithKline Wednesday reported second-quarter net income of 441 million pounds after a loss of 180 million pounds in the same period last year.

The company also announced a restructuring program aiming to improve competitiveness and cut costs by 400 million pounds annually by 2021. GlaxoSmithKline also agreed to invest $300 million in personal genetic testing service 23andMe as part of deal to use the company's database to develop precision targeted drugs.

You may also interested in

Asian markets lower after Wall Street decline

Sep 15, 2016

Asian stock markets were mostly lower Thursday following Wall Street's decline in light trading...

McDonald's sells China business in deal worth up...

Jan 9, 2017

Fast-food giant McDonald's is selling a controlling stake in its China business to a group of...

China pledges further cuts in excess steel, coal...

Jan 10, 2017

China's top economic planner has pledged to continue cutting steel and coal production, which have...

China auto market has bumper year but 2017...

Jan 12, 2017

Industry figures show China's auto market had a bumper year in 2016 as sales grew by 15 percent,...

China exports shrink as Trump trade tensions loom

Jan 13, 2017

China's exports fell back into contraction again last month, signaling renewed weakness for the...

About Us

Frontal Report is an emerging leader in all forms of media. We aim to be the leading news brand for readers around the world.

Contact us: sales[at]frontalreport.com

Subscribe Now!